Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression

American Journal of Human Genetics

Volumn 68, Issue 6, 2001, Pages 1428-1436

  Brophy, Victoria H ^a   Jampsa, Rachel L ^a   Clendenning, James B ^a   McKinstry, Laura A ^a   Jarvik, Gail P ^a   Furlong, Clement E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; MUTANT PROTEIN; ORGANOPHOSPHORUS COMPOUND; UNCLASSIFIED DRUG; ARYLESTERASE; CARBOXYLESTERASE; ESTERASE; MESSENGER RNA; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; PON1 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; HYDROLYSIS; MAJOR CLINICAL STUDY; PEST CONTROL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATOR GENE; SEQUENCE ANALYSIS; BLOOD; CAUCASIAN; CELL CULTURE; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; GENOTYPE; LIVER CELL; MALE; METABOLISM; MOLECULAR GENETICS; MUTATION; PROMOTER REGION;

3' UNTRANSLATED REGIONS; ARYLDIALKYLPHOSPHATASE; CARBOXYLIC ESTER HYDROLASES; CELLS, CULTURED; ESTERASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; GENOTYPE; HEPATOCYTES; HUMANS; HYDROLYSIS; LINKAGE DISEQUILIBRIUM; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PHENYLACETATES; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RNA, MESSENGER;

EID: 0034743754     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/320600     Document Type: Article

References (56)

1. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
2. An enzyme hydrolysing diethyl-p-nitrophenyl phosphate (E-600) and its identity with the A-esterase of mammalian sera
3. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
4. Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: Studies in humans and in atherosclerotic apolipoprotein E-deficient mice
5. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase
6. Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism
7. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters
8. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
9. Polymorphisms in the human paraoxonase (PON1) promoter
10. Analysis of paraoxonase (PON1) L55M status requires both genotype and phenotype
11. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism
12. Mutations in the human paraoxonase 1 gene: Frequencies, allelic linkages, and association with coronary artery disease
13. Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity
14. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
15. Further evidence for the concept of bovine plasma arylesterase as a lipoprotein
16. Alternative poly(A) site selection in complex transcription units: Means to an end?
17. Human and rabbit paraoxonase: Purification, cloning, sequencing, mapping and role of the polymorphism in organophosphate detoxication
18. Genetically determined susceptibility to organophosphorus insecticides and nerve agents: Developing a mouse model for the human PON1 polymorphism
19. Spectrophotometric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos and parathion by plasma paraoxonase/arylesterase
20. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon
21. On the genetics of the human serum paraoxonase (EC 3.1.1.2)
22. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation
23. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism
24. The molecular basis of the human serum paraoxonase activity polymorphism
25. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases
26. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease
27. Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients
28. 55 genotype
29. Effects of lipid removal on the molecular size and kinetic properties of bovine plasma arylesterase
30. Analysis of the serum paraoxonase/arylesterase polymorphism in some Sudanese families
31. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
32. Two alleles of the human paraoxonase gene produce different amounts of mRNA: An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism
33. Serum paraoxonase status: A major factor in determining resistance to organophosphates
34. Catalytic efficiency determines the in-vivo efficacy of PON1 for detoxifying organophosphorus compounds
35. Paraoxonase protects against chlorpyrifos toxicity in mice
36. Atherosclerosis
37. Human serum paraoxonase
38. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
39. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
40. The separation of sheep and human serum "A"-esterase activity into the lipoprotein fraction by ultracentrifugation
41. A simple salting out procedure for extracting DNA from human nucleated cells
42. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols
43. Genetic polymorphism and interethnic variability of plasma paroxonase activity
44. A SAF binding site in the promoter region of human γ-fibrinogen gene functions as an IL-6 response element
45. Determination of paraoxonase (PON1) status requires more than genotyping
46. Serum paraoxonase activity and genotype distribution in Japanese patients with diabetes mellitus
47. Paraoxonase PON1 polymorphism Leu-Met54 is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study
48. Point mutations in AAUAAA and the poly (A) addition site: Effects on the accuracy and efficiency of cleavage and polyadenylation in vitro
49. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
50. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
51. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
52. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
53. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent
54. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men
55. Oxidized phospholipids induce changes in hepatic paraoxonase and apoJ but not monocyte chemoattractant protein-1 via interleukin-6
56. Protective effect of high density lipoprotein associated paraoxonase: Inhibition of the biological activity of minimally oxidized low density lipoprotein